FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079776736> ?p ?o ?g. }

• W2079776736 endingPage "1" @default.
• W2079776736 startingPage "1" @default.
• W2079776736 abstract "The evaluation and optimal use of rituximab in lymphoid malignancies Tadeusz Robak1, Pawel Robak2, Piotr Smolewski21Department of Hematology, 2Experimental Hematology, Medical University of Łódź, Łódź, PolandAbstract: Rituximab is an IgG1, chimeric monoclonal antibody (mAb) containing murine light- and heavy-chain variable-region sequences and human constant-region sequences. Rituximab targets the CD20 molecule expressed on normal and malignant B-lymphocytes. At present, rituximab is the most important mAb of clinical value in patients with B-cell lymphoid malignancies. Since approval in 1997, rituximab has become widely used in chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and diffused large B-cell lymphoma (DLBCL) when combined with chemotherapy. Currently, rituximab is commonly combined with first-line chemotherapy for FL and should be offered as maintenance therapy to all appropriate patients with this disease. Randomized Phase III trials demonstrated the superiority of rituximab added to CHOP chemotherapy against CHOP chemotherapy alone in patients with DLBCL. Rituximab alone has limited activity in MCL but can be used in MCL in combination with chemotherapy, despite the benefits not being as impressive as when used against other lymphoma entities. In addition, for the less frequent B-cell lymphomas, small series show considerable activity for most of these entities. Fludarabine and rituximab combination therapies in CLL yielded promising results in several studies. Two large Phase III randomized trials demonstrated the superiority of chemoimmunotherapy with rituximab compared with chemotherapy alone in previously untreated and refractory/relapsed patients with CLL. Therefore, it can be concluded that rituximab, with only few exceptions, can generally be accepted as a standard component of anti B-cell non-Hodgkin&#39;s lymphoma therapies. In this review, the pharmacology, mode of action, pharmacokinetics, and current place in the therapy of B-cell lymphoid malignancies of rituximab are presented. In addition, an overview of studies conducted to date and optimal use of this drug, including timing and doses, is presented.Keywords: chronic lymphocytic leukemia, combined therapy, rituximab, DLBCL, follicular lymphoma, NHL, side effects, pharmacokinetics" @default.
• W2079776736 created "2016-06-24" @default.
• W2079776736 creator A5017586611 @default.
• W2079776736 creator A5060741746 @default.
• W2079776736 creator A5069332579 @default.
• W2079776736 date "2012-01-01" @default.
• W2079776736 modified "2023-09-25" @default.
• W2079776736 title "The evaluation and optimal use of rituximab in lymphoid malignancies" @default.
• W2079776736 cites W139931011 @default.
• W2079776736 cites W147398146 @default.
• W2079776736 cites W1509374036 @default.
• W2079776736 cites W1564461906 @default.
• W2079776736 cites W1594668159 @default.
• W2079776736 cites W1605230984 @default.
• W2079776736 cites W1783223960 @default.
• W2079776736 cites W1852939045 @default.
• W2079776736 cites W1952288345 @default.
• W2079776736 cites W1963628010 @default.
• W2079776736 cites W1965280443 @default.
• W2079776736 cites W1973919081 @default.
• W2079776736 cites W1974712387 @default.
• W2079776736 cites W1975736815 @default.
• W2079776736 cites W1978235999 @default.
• W2079776736 cites W1979981121 @default.
• W2079776736 cites W1985460392 @default.
• W2079776736 cites W1988217711 @default.
• W2079776736 cites W1993067667 @default.
• W2079776736 cites W1993437245 @default.
• W2079776736 cites W1996008853 @default.
• W2079776736 cites W1996366496 @default.
• W2079776736 cites W1997353354 @default.
• W2079776736 cites W1998101000 @default.
• W2079776736 cites W1998127944 @default.
• W2079776736 cites W2001105476 @default.
• W2079776736 cites W2002840457 @default.
• W2079776736 cites W2004635475 @default.
• W2079776736 cites W2004961788 @default.
• W2079776736 cites W2005330444 @default.
• W2079776736 cites W2005575131 @default.
• W2079776736 cites W2008542227 @default.
• W2079776736 cites W2013265163 @default.
• W2079776736 cites W2013302190 @default.
• W2079776736 cites W2015021549 @default.
• W2079776736 cites W2022588086 @default.
• W2079776736 cites W2024303920 @default.
• W2079776736 cites W2027027364 @default.
• W2079776736 cites W2027374210 @default.
• W2079776736 cites W2029903885 @default.
• W2079776736 cites W2037980980 @default.
• W2079776736 cites W2046206081 @default.
• W2079776736 cites W2051648120 @default.
• W2079776736 cites W2052722931 @default.
• W2079776736 cites W2053625277 @default.
• W2079776736 cites W2054157335 @default.
• W2079776736 cites W2054312534 @default.
• W2079776736 cites W2058015212 @default.
• W2079776736 cites W2058767405 @default.
• W2079776736 cites W2063471628 @default.
• W2079776736 cites W2066045842 @default.
• W2079776736 cites W206701898 @default.
• W2079776736 cites W2072257248 @default.
• W2079776736 cites W2072620152 @default.
• W2079776736 cites W2073873436 @default.
• W2079776736 cites W2075141373 @default.
• W2079776736 cites W2075632612 @default.
• W2079776736 cites W2079341033 @default.
• W2079776736 cites W2079481807 @default.
• W2079776736 cites W2082312121 @default.
• W2079776736 cites W2088052288 @default.
• W2079776736 cites W2094684894 @default.
• W2079776736 cites W2096661684 @default.
• W2079776736 cites W2097852595 @default.
• W2079776736 cites W2099314298 @default.
• W2079776736 cites W2101648653 @default.
• W2079776736 cites W2103563361 @default.
• W2079776736 cites W2104746788 @default.
• W2079776736 cites W2104940816 @default.
• W2079776736 cites W2107567250 @default.
• W2079776736 cites W2112937953 @default.
• W2079776736 cites W21149459 @default.
• W2079776736 cites W2116262245 @default.
• W2079776736 cites W2117648265 @default.
• W2079776736 cites W2123187146 @default.
• W2079776736 cites W2123236288 @default.
• W2079776736 cites W2124285375 @default.
• W2079776736 cites W2125134816 @default.
• W2079776736 cites W2125684345 @default.
• W2079776736 cites W2126188262 @default.
• W2079776736 cites W2127749132 @default.
• W2079776736 cites W2130093747 @default.
• W2079776736 cites W2135270635 @default.
• W2079776736 cites W2136360293 @default.
• W2079776736 cites W2136868555 @default.
• W2079776736 cites W2138404218 @default.
• W2079776736 cites W2140606816 @default.
• W2079776736 cites W2140791665 @default.
• W2079776736 cites W2141593354 @default.
• W2079776736 cites W2141880470 @default.

• next